Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 24 studies | 32% ± 15% | |
oligodendrocyte | 17 studies | 72% ± 17% | |
endothelial cell of vascular tree | 11 studies | 31% ± 9% | |
fibroblast | 10 studies | 30% ± 18% | |
endothelial cell of artery | 9 studies | 40% ± 11% | |
astrocyte | 5 studies | 26% ± 7% | |
pericyte | 5 studies | 27% ± 10% | |
macrophage | 5 studies | 26% ± 9% | |
pancreatic A cell | 4 studies | 50% ± 29% | |
retinal pigment epithelial cell | 4 studies | 78% ± 7% | |
vein endothelial cell | 4 studies | 37% ± 11% | |
adipocyte | 4 studies | 25% ± 6% | |
pancreatic D cell | 3 studies | 36% ± 27% | |
connective tissue cell | 3 studies | 31% ± 11% | |
myeloid cell | 3 studies | 32% ± 1% | |
capillary endothelial cell | 3 studies | 33% ± 12% | |
plasmacytoid dendritic cell | 3 studies | 27% ± 8% | |
GABAergic neuron | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 87% | 3027.36 | 77 / 89 | 95% | 152.48 | 857 / 901 |
lung | 95% | 4727.99 | 548 / 578 | 84% | 22.86 | 974 / 1155 |
prostate | 88% | 3720.98 | 215 / 245 | 83% | 16.75 | 418 / 502 |
adrenal gland | 82% | 3628.34 | 211 / 258 | 89% | 50.33 | 204 / 230 |
breast | 100% | 12298.21 | 459 / 459 | 67% | 16.30 | 753 / 1118 |
brain | 83% | 8465.29 | 2184 / 2642 | 81% | 40.22 | 573 / 705 |
skin | 77% | 8370.76 | 1399 / 1809 | 82% | 63.83 | 386 / 472 |
uterus | 99% | 12819.96 | 169 / 170 | 42% | 14.92 | 194 / 459 |
intestine | 87% | 4043.15 | 844 / 966 | 47% | 9.69 | 246 / 527 |
bladder | 81% | 3811.95 | 17 / 21 | 51% | 9.36 | 256 / 504 |
stomach | 52% | 1367.94 | 186 / 359 | 62% | 11.22 | 178 / 286 |
pancreas | 20% | 435.97 | 67 / 328 | 87% | 36.26 | 154 / 178 |
adipose | 100% | 13082.61 | 1204 / 1204 | 0% | 0 | 0 / 0 |
ovary | 51% | 1665.06 | 91 / 180 | 43% | 6.08 | 184 / 430 |
lymph node | 0% | 0 | 0 / 0 | 93% | 59.19 | 27 / 29 |
thymus | 33% | 934.98 | 214 / 653 | 60% | 13.43 | 364 / 605 |
spleen | 91% | 3679.80 | 220 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 82% | 3187.73 | 1100 / 1335 | 0% | 0 | 0 / 0 |
liver | 6% | 105.96 | 14 / 226 | 73% | 26.98 | 295 / 406 |
esophagus | 35% | 816.08 | 501 / 1445 | 40% | 7.42 | 74 / 183 |
eye | 0% | 0 | 0 / 0 | 70% | 37.58 | 56 / 80 |
tonsil | 0% | 0 | 0 / 0 | 51% | 10.58 | 23 / 45 |
heart | 11% | 295.06 | 98 / 861 | 0% | 0 | 0 / 0 |
muscle | 11% | 239.37 | 91 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 5% | 126.02 | 47 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0048870 | Biological process | cell motility |
GO_2000394 | Biological process | positive regulation of lamellipodium morphogenesis |
GO_0006935 | Biological process | chemotaxis |
GO_0006955 | Biological process | immune response |
GO_0016192 | Biological process | vesicle-mediated transport |
GO_0034638 | Biological process | phosphatidylcholine catabolic process |
GO_0030149 | Biological process | sphingolipid catabolic process |
GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
GO_0030334 | Biological process | regulation of cell migration |
GO_0010634 | Biological process | positive regulation of epithelial cell migration |
GO_0009395 | Biological process | phospholipid catabolic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005886 | Cellular component | plasma membrane |
GO_0003676 | Molecular function | nucleic acid binding |
GO_0030247 | Molecular function | polysaccharide binding |
GO_0016787 | Molecular function | hydrolase activity |
GO_0047391 | Molecular function | alkylglycerophosphoethanolamine phosphodiesterase activity |
GO_0005044 | Molecular function | scavenger receptor activity |
GO_0004622 | Molecular function | lysophospholipase activity |
GO_0004528 | Molecular function | phosphodiesterase I activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005509 | Molecular function | calcium ion binding |
Gene name | ENPP2 |
Protein name | Alternative protein ENPP2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (E-NPP 2) (EC 3.1.4.39) (Autotaxin) (Extracellular lysophospholipase D) (LysoPLD) |
Synonyms | ATX PDNP2 |
Description | FUNCTION: Hydrolyzes lysophospholipids to produce the signaling molecule lysophosphatidic acid (LPA) in extracellular fluids . Major substrate is lysophosphatidylcholine . Can also act on sphingosylphosphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility . Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP . Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation . Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein . May have a role in induction of parturition . Possible involvement in cell proliferation and adipose tissue development (Probable). Tumor cell motility-stimulating factor . Required for LPA production in activated platelets, cleaves the sn-1 lysophospholipids to generate sn-1 lysophosphatidic acids containing predominantly 18:2 and 20:4 fatty acids . Shows a preference for the sn-1 to the sn-2 isomer of 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) . . |
Accessions | ENST00000522826.5 [Q13822-3] E5RIB9 Q13822 ENST00000520066.5 E7EUF1 ENST00000518958.1 ENST00000427067.6 E5RIA2 ENST00000259486.10 [Q13822-2] ENST00000522167.5 L8ECC9 ENST00000075322.11 [Q13822-1] E5RJ49 |